Oslo (Norway), 30 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that the first US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The RELEASE study spans across Europe, USA and Asia, with patient enrolment initiated in all continents.

Read the original post:
PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE study

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *